4-甲基硫代哌啶盐酸盐 | 208245-70-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 4-甲基硫代哌啶盐酸盐
• 英文名称: 4-(methylthio)piperidine hydrochloride
• 英文别名: 4-Methylthiopiperidine hydrochloride；4-methylsulfanylpiperidine;hydrochloride
• CAS: 208245-70-9
• 化学式: C₆H₁₃NS*ClH
• 分子量: 167.703
• InChiKey: VXAYZGLCMOYQFU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.52
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  37.3
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  4-甲基硫代哌啶盐酸盐 、 8-chloro-3-(5-(difluoromethyl)-1,3,4-thiadiazol-2-yl)-N-(1-methylcyclopropyl)imidazo[1,2-a]pyridine-6-sulfonamide 在 Pd-PEPPSI-(2,6-(3-pentyl)pentylphenyl-2H-imidazol-2-ylidene)^Cl-o-picoline 、 caesium carbonate 作用下， 以 1,4-二氧六环 为溶剂， 以22.42%的产率得到3-(5-(difluoromethyl)-1,3,4-thiadiazol-2-yl)-N-(1methylcyclopropyl)-8-(4-(methylthio)piperidin-1-yl)imidazo[1,2-a]pyridine-6-sulfonamide
  参考文献：
  名称：

  [EN] PARG INHIBITORY COMPOUNDS
  [FR] COMPOSÉS INHIBITEURS DE PARG

  摘要：

  The present invention relates to a compound of formula (I) or an enantiomer, diastereoisomer, tautomer, pharmaceutically acceptable solvate, pharmaceutically acceptable crystal form, pharmaceutically acceptable salt or a prodrug thereof. The present invention further relates to the compound of formula (I) of the present invention for use in therapy. Instant compounds are particularly useful as PARC inhibitors, and can be used in a method of treatment of a proliferative disorder, preferably of cancer.

  公开号：

  WO2023057389A1
• 作为产物：
  描述：

  1-Boc-4-甲烷磺酰氧基哌啶 在 盐酸 作用下， 以 1,4-二氧六环 、 甲醇 为溶剂， 反应 15.03h， 生成 4-甲基硫代哌啶盐酸盐
  参考文献：
  名称：

  [EN] BENZOXAZEPINES AS INHIBITORS OF P13K/MTOR AND METHODS OF THEIR USE AND MANUFACTURE
  [FR] BENZOXAZÉPINES UTILISÉES COMME INHIBITEURS DE P13K/MTOR ET PROCÉDÉS D'UTILISATION ET DE FABRICATION

  摘要：

  公开号：

  WO2012071509A3

文献信息

• [EN] BENZOXAZEPINES AS INHIBITORS OF MTOR AND METHODS OF THEIR USE AND MANUFACTURE<br/>[FR] BENZOXAZÈPINES COMME INHIBITEURS DE MTOR ET MÉTHODES D'UTILISATION ET DE FABRICATION
  申请人：EXELIXIS INC

  公开号：WO2010138490A1

  公开（公告）日：2010-12-02

  The invention is directed to inhibitors of mTOR and pharmaceutically acceptable salts or solvates thereof, as well as methods of using them. The inhibitors are generally of structural formula wherein the combination of R1 and R2 are as defined herein, and pharmaceutically acceptable salts thereof.

  这项发明涉及 mTOR 的抑制剂及其药用盐或溶剂，以及它们的使用方法。这些抑制剂通常具有结构式，其中 R1 和 R2 的组合如本文所定义，并且其药用盐。
• [EN] BENZOXAZEPINES AS INHIBITORS OF PI3K/m TOR AND METHODS OF THEIR USE AND MANUFACTURE<br/>[FR] BENZOXAZÉPINES COMME INHIBITEURS DE PI3K/M TOR, MÉTHODES D'UTILISATION ET DE FABRICATION BENZOXAZEPINES AS INHIBITORS OF PI3K/M TOR AND METHODS OF THEIR USE AND MANUFACTURE
  申请人：EXELIXIS INC

  公开号：WO2010138487A1

  公开（公告）日：2010-12-02

  The invention is directed to Compounds of Formula (I): the invention provides compounds that inhibit, regulate, and/or modulate P13K and/or mTOR that are useful in the treatment of hyperproliferative diseases, such as cancer, in mammals. This invention also provides methods of making the compound methods of using such compounds in the treatment of hyperproliferative diseases in mammals, especially humans, and to pharmaceutical compositions containing such compounds. For example, cancer in which activity against PI3fC-alph mTOR, or both contributes to its pathology and/or symptomatology include breast cancer mantle cell lymphoma, renal cell carcinoma, acute myelogenous leukemia, chronic myelogenous leukemia, NPM/ALK- transformed anaplastic large cell lymphoma, diffu large B cell lymphoma, rhabdomyosarcoma, ovarian cancer, endometrial cancer, cervic cancer, non small cell lung carcinoma, small cell lung carcinoma, adenocarcinoma, col cancer, rectal cancer, gastric carcinoma, hepatocellular carcinoma, melanoma, pancreat cancer, prostate carcinoma, thyroid carcinoma, anaplastic large cell lymphoma, hemangiom glioblastoma, or head and neck cancer.

  这项发明涉及式(I)的化合物：该发明提供了抑制、调节和/或调节P13K和/或mTOR的化合物，这些化合物在治疗哺乳动物的高增殖性疾病，如癌症，方面非常有用。该发明还提供了制备该化合物的方法，以及在治疗哺乳动物，特别是人类的高增殖性疾病中使用这些化合物的方法，以及含有这些化合物的药物组合物。例如，对PI3fC-α mTOR或两者都具有活性有助于其病理学和/或症状学的癌症包括乳腺癌、套细胞淋巴瘤、肾细胞癌、急性髓细胞白血病、慢性髓细胞白血病、NPM/ALK转化的间变性大细胞淋巴瘤、弥漫性大B细胞淋巴瘤、横纹肌肉瘤、卵巢癌、子宫内膜癌、宫颈癌、非小细胞肺癌、小细胞肺癌、腺癌、结肠癌、直肠癌、胃癌、肝细胞癌、黑色素瘤、胰腺癌、前列腺癌、甲状腺癌、间变性大细胞淋巴瘤、血管瘤、胶质母细胞瘤或头颈癌。
• [EN] COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY<br/>[FR] COMPOSÉS ET COMPOSITIONS SERVANT DE MODULATEURS DE L'ACTIVITÉ DE GPR119
  申请人：IRM LLC

  公开号：WO2009126535A1

  公开（公告）日：2009-10-15

  The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of GPR119; such as, but not limited to, diabetes, obesity and associated metabolic disorders. Formula (I) is a compound, in which A can have up to 2 ring -CH2- group substituted with -C(O)- and can be partially unsaturated with up to 2 double bonds; Wi and W2 are independently selected from CR10 and N; wherein R10 is selected from hydrogen and C1_6alkyl; Yi is selected from NRn, O and S; wherein Rn is selected from hydrogen and C1_ 6alkyl; Y2 and Y3 are independently selected from CH and N; Y4 is selected from CH2, OCH2 and NR15; wherein R15 is selected from hydrogen and C1_6alkyl; or the pharmaceutically acceptable salts thereof.

  本发明提供化合物、包含这些化合物的药物组合物以及使用这些化合物治疗或预防与GPR119活性相关的疾病或疾病，例如但不限于糖尿病、肥胖症和相关代谢障碍的方法。公式（I）是一种化合物，其中A可以有高达2个环-CH2-基团被-C（O）-取代，并且可以部分不饱和，具有高达2个双键；Wi和W2分别选自CR10和N；其中R10选自氢和C1_6烷基；Yi选自NRn、O和S；其中Rn选自氢和C1_6烷基；Y2和Y3分别选自CH和N；Y4选自 、O 和NR15；其中R15选自氢和C1_6烷基；或其药学上可接受的盐。
• Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture
  申请人：Aay Naing

  公开号：US20120258953A1

  公开（公告）日：2012-10-11

  The invention is directed to Compounds of Formula (I): the invention provides compounds that inhibit, regulate, and/or modulate P13K and/or mTOR that are useful in the treatment of hyperproliferative diseases, such as cancer, in mammals. This invention also provides methods of making the compound methods of using such compounds in the treatment of hyperproliferative diseases in mammals, especially humans, and to pharmaceutical compositions containing such compounds. For example, cancer in which activity against PI3fC-alph mTOR, or both contributes to its pathology and/or symptomatology include breast cancer mantle cell lymphoma, renal cell carcinoma, acute myelogenous leukemia, chronic myelogenous leukemia, NPM/ALK-transformed anaplastic large cell lymphoma, diffu large B cell lymphoma, rhabdomyosarcoma, ovarian cancer, endometrial cancer, cervic cancer, non small cell lung carcinoma, small cell lung carcinoma, adenocarcinoma, col cancer, rectal cancer, gastric carcinoma, hepatocellular carcinoma, melanoma, pancreat cancer, prostate carcinoma, thyroid carcinoma, anaplastic large cell lymphoma, hemangiom glioblastoma, or head and neck cancer.

  本发明涉及化合物I式的化合物：本发明提供了一种抑制、调节和/或调节P13K和/或mTOR的化合物，其在哺乳动物中治疗增殖过度性疾病，如癌症方面非常有用。本发明还提供了制备该化合物的方法，使用这些化合物在哺乳动物中治疗增殖过度性疾病的方法，特别是人类，并提供了包含这些化合物的制药组合物。例如，对于活性针对PI3fC-alph mTOR或两者都对其病理和/或症状学产生贡献的癌症，包括乳腺癌、曼托细胞淋巴瘤、肾细胞癌、急性髓性白血病、慢性髓性白血病、NPM / ALK转化的间变性大细胞淋巴瘤、弥漫性大B细胞淋巴瘤、横纹肌肉瘤、卵巢癌、子宫内膜癌、宫颈癌、非小细胞肺癌、小细胞肺癌、腺癌、结肠癌、直肠癌、胃癌、肝细胞癌、黑色素瘤、胰腺癌、前列腺癌、甲状腺癌、间变性大细胞淋巴瘤、血管瘤、胶质母细胞瘤或头颈癌。
• COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY
  申请人：Cow Christopher

  公开号：US20110263557A1

  公开（公告）日：2011-10-27

  The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of GPR119; such as, but not limited to, diabetes, obesity and associated metabolic disorders. Formula (I) is a compound, in which A can have up to 2 ring —CH2- group substituted with —C(O)— and can be partially unsaturated with up to 2 double bonds; Wi and W2 are independently selected from CR10 and N; wherein R10 is selected from hydrogen and C1_6alkyl; Yi is selected from NRn, O and S; wherein Rn is selected from hydrogen and C1_6alkyl; Y2 and Y3 are independently selected from CH and N; Y4 is selected from CH2, OCH2 and NR15; wherein R15 is selected from hydrogen and C1_6alkyl; or the pharmaceutically acceptable salts thereof.

  本发明提供化合物、含有这些化合物的药物组合物以及使用这些化合物治疗或预防与GPR119活性相关的疾病或疾病的方法，例如但不限于糖尿病、肥胖症和相关代谢紊乱。公式（I）是一种化合物，其中A可以有高达2个环-CH2-基团被取代为-C（O）-，并且可以部分不饱和，具有高达2个双键；Wi和W2分别从CR10和N中独立选择，其中R10从氢和C1_6烷基中选择；Yi从NRn、O和S中选择，其中Rn从氢和C1_6烷基中选择；Y2和Y3分别从CH和N中选择；Y4从 、O 和NR15中选择，其中R15从氢和C1_6烷基中选择；或其药学上可接受的盐。